Reading Time: 5 minutes There has recently been a flood of news stories on the outcomes of the Australian Phase 1 clinical trial investigating Copper ATSM (CuATSM) which is
Category: Treatments
Reading Time: 3 minutes This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 2 minutes The research team frequently gets asked about the effectiveness of alternative therapies and their use as treatments for MND. Here we report on a recent
Reading Time: 7 minutes In the last decade, the MND Association has invested millions in research within the UK and across the world. We are a leader in the
Reading Time: 2 minutes In their official press release published on 21 November 2017, Cytokinetics Inc. announced that they will not be continuing work on tirasemtiv after disappointing results
Reading Time: 3 minutes At last year’s Airlie House workshop to develop new ALS/MND Clinical Trial Guidelines the focus was, of course, on MND, but there was also important input
Causes and disease mechanisms Clinical Trials Markers of Disease Progression MND Research Research we fund
Lighthouse Project shines a beacon on HERVs and their role in ALS
Reading Time: 3 minutes There is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to
Reading Time: 5 minutes It’s been over a month since the announcement by the FDA of their decision to licence edaravone / Radicava for people with MND in the
Reading Time: 4 minutes Each year, the MND Association dedicates the month of June to raising MND awareness. This year, we focus on the eyes – in most people
Reading Time: 2 minutes On Friday 5 May in America, the FDA, the organisation that approves drugs, announced that they’d granted a licence for the drug known as a